EGFR and breast carcinoma: The targeting efficiency of the resulting nanoparticle against HER2‐positive breast cancer cells was assessed by flow cytometry and immunofluorescence.131 In addition, an epidermal growth factor–based nanoprobe (EGF‐NP) for in vivo optical imaging of epidermal growth factor receptor (EGFR) was developed.